Cornerstone Advisory’s Opus Genetics IRD Stock Holding History

Cornerstone Advisory’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	819
2021 Q4	$0	Buy	+1	New	+$4	﹤0.01%	851

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Cornerstone Advisory's IRD Position: Q1 2022 in Review

Cornerstone Advisory sold out of Opus Genetics (IRD) in Q1 2022, closing a stake of 1 share.

Cornerstone Advisory first reported a position in IRD in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 41 funds tracked by Wall St. Rank hold IRD as of Q1 2022.

Cornerstone Advisory reported no remaining Opus Genetics position as of Q1 2022 after selling out during the quarter.
Cornerstone Advisory sold 1 Opus Genetics share in Q1 2022.
Cornerstone Advisory first reported a position in Opus Genetics in Q4 2021 and held it in 1 quarter.
Cornerstone Advisory's Opus Genetics position peaked at $0 in Q4 2021.
41 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.